News from abbvie A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 15, 2014, 23:53 ET

AbbVie Board Recommends Stockholders Vote Against Shire Transaction

Following Shire plc's ("Shire") waiver of the three-day notice period, AbbVie Inc. ("AbbVie") (NYSE: ABBV) announces today its Board of...

Oct 14, 2014, 19:44 ET

Announcement Of Notice To Shire Of AbbVie Board Intention To Reconsider Recommendation

AbbVie Inc. ("AbbVie") announces it has notified Shire plc ("Shire") of its Board of Directors' intention to reconsider the recommendation made on...

Oct 13, 2014, 11:43 ET
http://www.multivu.com/players/English/7298751-abbvie-phase-3-hidradenitis-suppurativa-trial-results/gallery/image/f1f12d6c-637d-46c9-8c65-812b7bf1c884.HR.jpg

AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress

AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab)  in...

Oct 06, 2014, 08:00 ET
Oct 01, 2014, 10:05 ET

AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting®

AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The...

Sep 27, 2014, 06:45 ET

AbbVie Presents Results from Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress

 AbbVie (NYSE: ABBV) released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with...

Sep 25, 2014, 08:00 ET

AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease

AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for reducing signs and...

Sep 22, 2014, 08:00 ET

AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting

 AbbVie (NYSE: ABBV) announced that data from several clinical studies evaluating potential new medicines in the company's oncology pipeline...

Sep 19, 2014, 14:08 ET

AbbVie Declares Quarterly Dividend

 The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.42 per share.  The cash dividend is payable...

Sep 11, 2014, 03:00 ET

AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease

AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing...

Sep 05, 2014, 08:00 ET

AbbVie to Present at Morgan Stanley Global Healthcare Conference

 AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014. Bill Chase, executive...

Sep 03, 2014, 16:05 ET

Revised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance

Following the announcement of the collaboration agreements with Calico Life Sciences LLC (Calico) and Infinity Pharmaceuticals Inc (Infinity),...

Sep 03, 2014, 13:00 ET

AbbVie And Calico Announce A Novel Collaboration To Accelerate The Discovery, Development And Commercialization Of New Therapies

 AbbVie (NYSE: ABBV) and Calico announced a novel R&D collaboration intended to help the two companies discover, develop and bring to...

Sep 03, 2014, 06:45 ET

Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology

 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE: ABBV) today announced that they have entered into a global...

Aug 28, 2014, 11:45 ET

AbbVie submete à aprovação da ANVISA seu novo tratamento para hepatite C, totalmente oral e livre de Interferon

 A AbbVie submeteu a Agência Nacional de Vigilância Sanitária (ANVISA) pedido de aprovação para...

Aug 18, 2014, 11:00 ET

AbbVie Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards

  AbbVie today announced the 40 outstanding students with cystic fibrosis (CF) who will each receive $2,500 to pursue their undergraduate or...

Aug 04, 2014, 08:00 ET

AbbVie Receives EMA and FDA Orphan Drug Designation for Investigational Compound ABT-414 in the Treatment of Glioblastoma Multiforme

AbbVie (NYSE:ABBV) today announced the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug...

Aug 01, 2014, 10:00 ET

AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program

 AbbVie (NYSE: ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a partnership to expand awareness of proper nutritional...

Jul 25, 2014, 07:47 ET

AbbVie Reports Second-Quarter 2014 Financial Results

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD...

Jul 23, 2014, 12:44 ET

AbbVie to Host Second-Quarter Earnings Conference Call

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD...